Cargando…

Current usage and challenges of master protocols—based on survey results by ASA BIOP oncology methodology working group master protocol sub-team

BACKGROUND: Master protocol trials, such as basket trials, umbrella trials or platform trials, have the potential of increasing efficiency in modern drug development. Meanwhile, though the concept of master protocol is getting more and more accepted, many challenges exist from design to implementati...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaoyun, Lu, Chengxing, Broglio, Kristine, Bycott, Paul, Chen, Jie, Jiang, Qi, Lin, Jianchang, Ye, Jingjing, Yin, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577726/
https://www.ncbi.nlm.nih.gov/pubmed/36267733
http://dx.doi.org/10.21037/atm-21-6139
_version_ 1784811822304460800
author Li, Xiaoyun
Lu, Chengxing
Broglio, Kristine
Bycott, Paul
Chen, Jie
Jiang, Qi
Lin, Jianchang
Ye, Jingjing
Yin, Jun
author_facet Li, Xiaoyun
Lu, Chengxing
Broglio, Kristine
Bycott, Paul
Chen, Jie
Jiang, Qi
Lin, Jianchang
Ye, Jingjing
Yin, Jun
author_sort Li, Xiaoyun
collection PubMed
description BACKGROUND: Master protocol trials, such as basket trials, umbrella trials or platform trials, have the potential of increasing efficiency in modern drug development. Meanwhile, though the concept of master protocol is getting more and more accepted, many challenges exist from design to implementation of these trials. To understand current usage and challenges of master protocol trials in action, American Statistical Association (ASA) Biopharmaceutical Section (BIOP) Oncology Methods Scientific Working Group Master Protocol Sub-team conducted a survey with the goal of providing valuable information for the community to understand the current usage of master protocol, with the goal to identify the challenges. METHODS: A total of 19 questions were included in an online survey that was distributed between April and May 2021. To avoid over-reporting within an organization, a pre-determined list of contacts from 37 organizations were reached out with the shared online link of the survey. Literature research and experience from the working group on challenges of master protocols are also summarized and discussed extensively. RESULTS: A total of 39 responses were received from 37 organizations. Thirty-one (79%) respondents indicated that they had trials with master protocol(s) in planning or implementation in their organization with most applications (54%) in oncology. Self-reported challenges on trial design, regulatory engagement and trial implementations were further summarized in the report. CONCLUSIONS: The survey results were consistent with previous literatures and expectations of members from the Scientific Working Group Sub-team. Multiple stakeholders are called to work collaboratively to remove roadblocks for future usage of master protocol trials.
format Online
Article
Text
id pubmed-9577726
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-95777262022-10-19 Current usage and challenges of master protocols—based on survey results by ASA BIOP oncology methodology working group master protocol sub-team Li, Xiaoyun Lu, Chengxing Broglio, Kristine Bycott, Paul Chen, Jie Jiang, Qi Lin, Jianchang Ye, Jingjing Yin, Jun Ann Transl Med Review Article on Challenges in Clinical Trials BACKGROUND: Master protocol trials, such as basket trials, umbrella trials or platform trials, have the potential of increasing efficiency in modern drug development. Meanwhile, though the concept of master protocol is getting more and more accepted, many challenges exist from design to implementation of these trials. To understand current usage and challenges of master protocol trials in action, American Statistical Association (ASA) Biopharmaceutical Section (BIOP) Oncology Methods Scientific Working Group Master Protocol Sub-team conducted a survey with the goal of providing valuable information for the community to understand the current usage of master protocol, with the goal to identify the challenges. METHODS: A total of 19 questions were included in an online survey that was distributed between April and May 2021. To avoid over-reporting within an organization, a pre-determined list of contacts from 37 organizations were reached out with the shared online link of the survey. Literature research and experience from the working group on challenges of master protocols are also summarized and discussed extensively. RESULTS: A total of 39 responses were received from 37 organizations. Thirty-one (79%) respondents indicated that they had trials with master protocol(s) in planning or implementation in their organization with most applications (54%) in oncology. Self-reported challenges on trial design, regulatory engagement and trial implementations were further summarized in the report. CONCLUSIONS: The survey results were consistent with previous literatures and expectations of members from the Scientific Working Group Sub-team. Multiple stakeholders are called to work collaboratively to remove roadblocks for future usage of master protocol trials. AME Publishing Company 2022-09 /pmc/articles/PMC9577726/ /pubmed/36267733 http://dx.doi.org/10.21037/atm-21-6139 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Review Article on Challenges in Clinical Trials
Li, Xiaoyun
Lu, Chengxing
Broglio, Kristine
Bycott, Paul
Chen, Jie
Jiang, Qi
Lin, Jianchang
Ye, Jingjing
Yin, Jun
Current usage and challenges of master protocols—based on survey results by ASA BIOP oncology methodology working group master protocol sub-team
title Current usage and challenges of master protocols—based on survey results by ASA BIOP oncology methodology working group master protocol sub-team
title_full Current usage and challenges of master protocols—based on survey results by ASA BIOP oncology methodology working group master protocol sub-team
title_fullStr Current usage and challenges of master protocols—based on survey results by ASA BIOP oncology methodology working group master protocol sub-team
title_full_unstemmed Current usage and challenges of master protocols—based on survey results by ASA BIOP oncology methodology working group master protocol sub-team
title_short Current usage and challenges of master protocols—based on survey results by ASA BIOP oncology methodology working group master protocol sub-team
title_sort current usage and challenges of master protocols—based on survey results by asa biop oncology methodology working group master protocol sub-team
topic Review Article on Challenges in Clinical Trials
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577726/
https://www.ncbi.nlm.nih.gov/pubmed/36267733
http://dx.doi.org/10.21037/atm-21-6139
work_keys_str_mv AT lixiaoyun currentusageandchallengesofmasterprotocolsbasedonsurveyresultsbyasabioponcologymethodologyworkinggroupmasterprotocolsubteam
AT luchengxing currentusageandchallengesofmasterprotocolsbasedonsurveyresultsbyasabioponcologymethodologyworkinggroupmasterprotocolsubteam
AT brogliokristine currentusageandchallengesofmasterprotocolsbasedonsurveyresultsbyasabioponcologymethodologyworkinggroupmasterprotocolsubteam
AT bycottpaul currentusageandchallengesofmasterprotocolsbasedonsurveyresultsbyasabioponcologymethodologyworkinggroupmasterprotocolsubteam
AT chenjie currentusageandchallengesofmasterprotocolsbasedonsurveyresultsbyasabioponcologymethodologyworkinggroupmasterprotocolsubteam
AT jiangqi currentusageandchallengesofmasterprotocolsbasedonsurveyresultsbyasabioponcologymethodologyworkinggroupmasterprotocolsubteam
AT linjianchang currentusageandchallengesofmasterprotocolsbasedonsurveyresultsbyasabioponcologymethodologyworkinggroupmasterprotocolsubteam
AT yejingjing currentusageandchallengesofmasterprotocolsbasedonsurveyresultsbyasabioponcologymethodologyworkinggroupmasterprotocolsubteam
AT yinjun currentusageandchallengesofmasterprotocolsbasedonsurveyresultsbyasabioponcologymethodologyworkinggroupmasterprotocolsubteam